Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.

[1]  C. Montón,et al.  A step‐down protocol for omalizumab treatment in oral corticosteroid‐dependent allergic asthma patients , 2018, British journal of clinical pharmacology.

[2]  T. Casale,et al.  Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma , 2017, Allergy.

[3]  M. Schatz,et al.  Oral corticosteroid exposure and adverse effects in asthmatic patients , 2018, The Journal of allergy and clinical immunology.

[4]  P. Greenberger,et al.  Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. , 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[5]  L. Wood,et al.  Role of Obesity in Asthma: Mechanisms and Management Strategies , 2017, Current Allergy and Asthma Reports.

[6]  W. Busse,et al.  A randomized multicenter study evaluating Xolair persistence of response after long‐term therapy , 2017, The Journal of allergy and clinical immunology.

[7]  N. Chueca,et al.  Obesity and Asthma: A Missing Link , 2017, International journal of molecular sciences.

[8]  K. Berhane,et al.  Effects of Childhood Asthma on the Development of Obesity among School‐aged Children , 2017, American journal of respiratory and critical care medicine.

[9]  M. Rogers,et al.  Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study , 2017, British Medical Journal.

[10]  J. Halterman,et al.  Physical activity, restrictions in activity, and body mass index among urban children with persistent asthma. , 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[11]  R. Gangnon,et al.  Relationships among aeroallergen sensitization, peripheral blood eosinophils, and periostin in pediatric asthma development , 2017, The Journal of allergy and clinical immunology.

[12]  W. Teague,et al.  Allergen Sensitization Is Associated with Increased Rates of Exacerbations, Oral Corticosteroid (OCS) Use, and Asthma-Related Healthcare Services in Children with Severe or Poorly Controlled Asthma , 2017 .

[13]  L. Bacharier,et al.  Activity and School Impairment By EPR-3 Asthma Control Guidelines in Children with Severe or Difficult-to-Treat Asthma , 2017 .

[14]  E. Bleecker,et al.  Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations , 2016, American journal of respiratory and critical care medicine.

[15]  M. Hew,et al.  Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life , 2016, Respirology.

[16]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[17]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[18]  M. Broder,et al.  Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis , 2016, ClinicoEconomics and outcomes research : CEOR.

[19]  J. Corren,et al.  Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. , 2016, Chest.

[20]  C. Lemière,et al.  Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. , 2016, Chest.

[21]  E. Bateman,et al.  Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. , 2016, The Lancet. Respiratory medicine.

[22]  D. Umetsu.  Mechanisms by which obesity impacts upon asthma , 2016, Thorax.

[23]  T. Ritz,et al.  Asthma Trigger Reports Are Associated with Low Quality of Life, Exacerbations, and Emergency Treatments. , 2016, Annals of the American Thoracic Society.

[24]  T. Omachi,et al.  Poor Asthma Control Is Associated with Overall Daily Activity Impairment: 3-Year Data from the EXCELS Study of Omalizumab , 2016 .

[25]  Anand A. Dalal,et al.  Utilization and Costs of Severe Uncontrolled Asthma in a Managed-Care Setting. , 2016, The journal of allergy and clinical immunology. In practice.

[26]  Su-Jau Yang,et al.  Hypertension and Asthma: A Comorbid Relationship. , 2016, The journal of allergy and clinical immunology. In practice.

[27]  P. Gergen,et al.  Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. , 2015, The Journal of allergy and clinical immunology.

[28]  R. Maciuca,et al.  Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies , 2015, Thorax.

[29]  E. Bateman,et al.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.

[30]  C. Bachert,et al.  Local Immunoglobulin E in the Nasal Mucosa: Clinical Implications , 2015, Allergy, asthma & immunology research.

[31]  G. Braunstahl,et al.  Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting , 2014, Biologics in therapy.

[32]  W. Busse,et al.  Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. , 2014, The Lancet. Respiratory medicine.

[33]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[34]  B. Chipps,et al.  Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. , 2014, The journal of allergy and clinical immunology. In practice.

[35]  Xu Yang,et al.  Comorbidity between depression and asthma via immune-inflammatory pathways: a meta-analysis. , 2014, Journal of affective disorders.

[36]  M. Castro,et al.  Coexisting chronic conditions associated with mortality and morbidity in adult patients with asthma , 2014, The Journal of asthma : official journal of the Association for the Care of Asthma.

[37]  P. Gibson.  Obesity and asthma. , 2013, Annals of the American Thoracic Society.

[38]  Su-Jau Yang,et al.  Overweight/obesity and risk of seasonal asthma exacerbations. , 2013, The journal of allergy and clinical immunology. In practice.

[39]  C. Koebnick,et al.  Increased asthma risk and asthma-related health care complications associated with childhood obesity. , 2013, American journal of epidemiology.

[40]  C. Ulrik,et al.  Obesity and asthma: a coincidence or a causal relationship? A systematic review. , 2013, Respiratory medicine.

[41]  A. Dixon,et al.  Effects of obesity and weight loss on airway physiology and inflammation in asthma. , 2013, Pulmonary pharmacology & therapeutics.

[42]  G. Braunstahl,et al.  The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma. , 2013, Respiratory medicine.

[43]  W. Busse,et al.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. , 2013, American journal of respiratory and critical care medicine.

[44]  R. Lockey,et al.  Asthma and comorbidities , 2013, Current opinion in allergy and clinical immunology.

[45]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[46]  C. Brightling,et al.  A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma , 2012, European Respiratory Journal.

[47]  I. Urrutia,et al.  Impact of Anxiety and Depression on Disease Control and Quality of Life in Asthma Patients , 2012, The Journal of asthma : official journal of the Association for the Care of Asthma.

[48]  D. Gioulekas,et al.  Asthma Control Test Is Correlated to FEV1 and Nitric Oxide in Greek Asthmatic Patients: Influence of Treatment , 2011, The Journal of asthma : official journal of the Association for the Care of Asthma.

[49]  Margaret W Leigh,et al.  An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. , 2011, American journal of respiratory and critical care medicine.

[50]  W. Busse,et al.  Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy , 2011, Annals of Internal Medicine.

[51]  P. Gergen,et al.  Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. , 2011, The New England journal of medicine.

[52]  J. Celedón,et al.  An official American Thoracic Society Workshop report: obesity and asthma. , 2010, Proceedings of the American Thoracic Society.

[53]  B. Lipworth,et al.  The minimal clinically important difference in allergic rhinitis , 2010, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[54]  P. Ferreira,et al.  Qualidade de vida em doentes com asma , 2010 .

[55]  P. Ferreira,et al.  Quality of life in asthma patients. , 2010, Revista portuguesa de pneumologia.

[56]  S. Bonini,et al.  Close correlation between anxiety, depression, and asthma control. , 2010, Respiratory medicine.

[57]  Mark Kosinski,et al.  The minimally important difference of the Asthma Control Test. , 2009, The Journal of allergy and clinical immunology.

[58]  S. Szefler,et al.  Baseline characteristics of patients enrolled in EXCELS: a cohort study. , 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[59]  C. Rand,et al.  Does higher body mass index contribute to worse asthma control in an urban population? , 2009, The Journal of allergy and clinical immunology.

[60]  G. Marshall,et al.  The logarithmic transformation and the geometric mean in reporting experimental IgE results: what are they and when and why to use them? , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[61]  D. Mannino,et al.  Body mass index and asthma severity in the National Asthma Survey , 2007, Thorax.

[62]  B. Dahme,et al.  Association of depression and anxiety with health care use and quality of life in asthma patients. , 2007, Respiratory medicine.

[63]  E. Juniper,et al.  Modification of the asthma quality of life questionnaire (standardised) for patients 12 years and older , 2005, Health and quality of life outcomes.

[64]  L. Heaney,et al.  Prevalence of psychiatric morbidity in a difficult asthma population: relationship to asthma outcome. , 2005, Respiratory medicine.

[65]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[66]  T. Platts-Mills,et al.  Physical activity and exercise in asthma: relevance to etiology and treatment. , 2005, The Journal of allergy and clinical immunology.

[67]  J Bousquet,et al.  Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.

[68]  Y. Oba,et al.  Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. , 2004, The Journal of allergy and clinical immunology.

[69]  Philip Marcus,et al.  Development of the asthma control test: a survey for assessing asthma control. , 2004, The Journal of allergy and clinical immunology.

[70]  K. Svensson,et al.  PRP11 THE VALIDITY OF THE WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE FOR PATIENTS WITH ASTHMA (WPAIASTHMA): RESULTS FROM A WEB-BASED STUDY , 2003 .

[71]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[72]  R. Townley,et al.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. , 2001, The European respiratory journal.

[73]  Ferrié,et al.  Development and validation of the Mini Rhinoconjunctivitis Quality of Life Questionnaire , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[74]  Third Expert Panel on theDiagnosis,et al.  Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .

[75]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[76]  G H Guyatt,et al.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire. , 1994, Journal of clinical epidemiology.